Profile of dupilumab and its potential in the treatment of inadequately controlled moderate-to-severe atopic dermatitis

Olabola Awosika
Lori Kim
Momina Mazhar
Monica Rengifo-Pardo
Alison Ehrlich

1 Department of Dermatology, The George Washington Medical Faculty Associates, Washington, DC, USA; 2 George Washington University School of Medicine & Health Sciences, Washington, DC, USA

Abstract: Atopic dermatitis (AD) is a common inflammatory skin disorder that manifests as eczematous lesions, often associated with allergic rhinitis and asthma. Historically, moderate-to-severe disease has been managed with systemic immunosuppression, such as oral corticosteroids, which result in relapse and limiting side effects. Due to recent advancements in the identification of interleukin (IL)-4 and IL-13 as key mediators in AD, new biological agents have been developed for treatment. Dupilumab is a recently approved monoclonal antibody that targets the alpha subunit of the IL-4 receptor and, thus, downregulates activity of IL-4 and IL-13. This review discusses the profile of dupilumab and its potential for efficacy and safety in treating moderate-to-severe AD by reviewing data from Phase I–III clinical trials. Results suggest that dupilumab shows great therapeutic promise for AD. Further studies investigating extended use of dupilumab and dupilumab in comparison to other agents are needed to establish long-term efficacy and safety.

Keywords: atopic dermatitis, dupilumab, IL-4, IL-13, biologics

Background

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by erythema, pruritus, and scaling of skin. AD is clinically diagnosed by these essential features, and the diagnosis is supported by early age of onset, personal or family history of atopy, and xerosis.1 AD has a complex, heterogeneous etiology that includes barrier defects, intrinsic immunological hyperactivity, and extrinsic triggers.2,3 According to a recent study of lifetime worldwide AD prevalence over the period of 1990–2010, there is no overall global trend in the prevalence of AD.4 However, a steady increase in AD prevalence in developing countries has been observed. In general, AD is estimated to affect up to 20% of children in developed countries and 3% of adults worldwide, with up to 50% of pediatric AD cases persisting into adulthood.5,6 In the USA, 10.7% of children and 3.2% of adults are living with AD.7,8

For patients with moderate-to-severe AD, skin lesions encompassing large surface areas are often associated with severe itching. These lesions can cause sleep disturbances and, in turn, symptoms of anxiety, depression, and poor quality of life.9 Topical steroids, topical immunomodulators, and phototherapy are often inadequate in providing sustained improvement in these patients, despite the additive benefit of topicals in decreasing inflammation and restoring epidermal barrier function.2 For patients with poor response to these topicals, the mainstay of treatment is systemic immunosuppression, including oral corticosteroids, cyclosporine, or mycophenolate...
mofetil. Though these medications may provide moderate relief in AD, the risks often outweigh the benefits of long-term use. In particular, these oral agents are associated with significant side effects such as increased infections, nausea/vomiting, hypertension, and headaches. In a 10-year chart review of the use of oral immunosuppressive drugs in patients with severe AD, frequent reasons for discontinuation of these therapies included ineffectiveness and adverse events, such as neurological symptoms, gastrointestinal upset, and fatigue/flu-like symptoms. Furthermore, for patients with renal impairment and uncontrolled hypertension, oral corticosteroids, mycophenolate mofetil, and cyclosporine are less viable treatment options due to their high risk to exacerbate the underlying comorbidities.

Given the poor therapeutic responses, inconveniences, and therapy-limiting side effects of conventional systemic AD therapeutics, there is a substantial unmet need for more efficacious and promising agents for moderate-to-severe AD with minimal adverse effects. With recent advances in the understanding of the pathological mechanisms of AD, new biological agents have been developed and are being evaluated in clinical trials. In March 2017, dupilumab became the first biologic to be approved by the US Food and Drug Administration for inadequately controlled moderate-to-severe AD. The drug received this approval because of its significant demonstration of efficacy and safety in treating AD in three randomized Phase III pivotal trials. The purpose of this article is to review the findings on dupilumab in clinical trials and examine the potential of the drug for inadequately controlled moderate-to-severe AD.

Methods

Relevant articles on disease activity in AD and clinical trials of dupilumab were searched and selected from the databases of PubMed and ClinicalTrials.gov using the following terms: dupilumab, AD, disease activity, interleukin (IL)-4, IL-13, thymus and activation-regulated chemokine (TARC), eotaxin 3 (CCL26), comorbidity, quality of life, efficacy, biologic, and adverse effects. Additional publications were collected from references identified in articles and related citations in PubMed. As of June 2017, Phase I, II, and III clinical trials of dupilumab have been published. In total, 31 relevant papers were reviewed and referenced.

Results

Pathogenesis and disease activity in AD

Ongoing debates regarding the pathogenesis of AD have led to the following description of two forms of the disease:

1. Intrinsic form resulting from abnormal epidermal structure and function.
2. Extrinsic form due to cutaneous inflammation caused by immune responses to extrinsic antigens.

Moreover, there has been identification of increased activity of T lymphocytes secreting effector cytokines and dysregulation of both cell-mediated immune responses and inflammatory cascades in AD skin. Yet, over the past several years, attention has been turned specifically toward type 2 inflammatory mediators as targets for AD therapy.

In particular, IL-4 and IL-13, cytokines from Th2 helper type 2 (Th2) cells, are key mediators of the inflammation in AD. These cytokines upregulate the expression of chemokines such as TARC and CCL26. This increased expression of TARC and CCL26 relates to increased disease activity, including the selective migration of Th2 lymphocytes and eosinophils into AD lesions, which cause inflammation. Additionally, in synergy with Toll-like receptor 2 ligands, IL-4 potentiates the chronicity of AD through IL-4-mediated suppression of IL-10. IL-4 and IL-13 also decrease the keratinocyte expression of barrier proteins, such as filaggrin, involucrin, and loricrin, triggering epidermal hyperplasia. Additional effects of these cytokines on keratinocytes include the suppression of keratinocyte differentiation and the synthesis of antimicrobial peptides and lipids. This activity further disrupts the skin barrier through aberrant expression of human β-defensins (hBD-2 and hBD-3) and cathelicidin (LL-37) leading to an increase in the susceptibility of lesional skin to infection by microorganisms, such as Staphylococcus aureus. Moreover, IL-4 and IL-13 induce B-cell differentiation leading to immunoglobulin E (IgE) class switching. This phenomenon explains the elevation of IgE levels in AD, which is often associated with the extrinsic form of the disease. Given that both IL-4 and IL-13 act through a common receptor (IL-4 receptor alpha; IL-4Rα), IL-4Rα has become a target of interest in treating AD. Inhibition of IL-4Rα has resulted in normalization of skin gene expression from lesional toward nonlesional skin, reduction of TARC expression, and efficacy in the suppression of itch.

Dupilumab: mechanism of action

Dupilumab is a fully human monoclonal antibody that binds to the IL-4Rα, resulting in inhibition of both IL-4 and IL-13 signaling. This blockade by dupilumab reduces the type 2 helper T-cell-mediated inflammation cascade in AD. Specifically, competitive inhibition at the IL-4Rα inhibits activation of the signal transducer and activator of transcription (STAT) and block the binding of IL-4 to the IL-4 receptor alpha (IL-4Rα), leading to inhibition of the downstream signaling cascade.
Dupilumab is a monoclonal antibody that targets the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways. It specifically binds to the IL-4Rα subunit of both type I and type II IL-4 receptors, leading to inhibition of the JAK/STAT signaling cascade.

**Dupilumab: Phase I trials**

In two 4-week randomized, double-blind, placebo-controlled, dose-increasing Phase I trials, dupilumab was evaluated as a monotherapy for moderate-to-severe AD in adults. In the M4A trial, 30 subjects received 75, 150, or 300 mg of subcutaneous dupilumab or placebo weekly for 4 weeks. The subjects were randomly assigned to receive placebo or dupilumab in a 1:4 ratio. In the M4B trial, 37 subjects were studied with 150 or 300 mg of subcutaneous dupilumab or placebo weekly for 4 weeks. These subjects were also randomized to receive placebo or dupilumab, but in a 1:3 ratio. Both the M4A and M4B trials were designed to assess safety as the primary end point. From composite analysis of both studies, by day 29, 59% of patients receiving dupilumab showed 50% reduction in the Eczema Area and Severity Index (EASI) score (EASI-50) compared to 19% of the placebo group (Table 1). In addition, significant improvements in Investigator Global Assessment (IGA) scores and pruritus scores for all dupilumab doses combined were observed in both studies. Concerning safety data, nasopharyngitis and headache were the most common side effects with no evidence of serious adverse events in either trial.

In addition to clinical improvement and safety, gene expression profiles of lesional sites after 150 and 300 mg dupilumab shifted to a more nonlesional molecular phenotype within 4 weeks. Lesional skin showed overall improvement in transcriptome by 24% in the 150 mg dose group and 49% in 300 mg dose group compared to 21% in the placebo group. Notably, markers of epidermal proliferation...
Table 1 Clinical efficacy and safety in Phase I–II trials

<table>
<thead>
<tr>
<th>Study groups</th>
<th>Placebo (N=16)</th>
<th>Dupilumab (N=51)</th>
<th>Placebo (N=54)</th>
<th>Dupilumab (N=55)</th>
<th>Placebo + topical GCS (N=10)</th>
<th>Dupilumab + topical GCS (N=21)</th>
<th>Placebo (N=61)</th>
<th>Dupilumab (N=63)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase Ia 4 weeks (day 29)</td>
<td>19</td>
<td>59</td>
<td>20</td>
<td>69</td>
<td>35</td>
<td>85</td>
<td>50</td>
<td>100</td>
</tr>
<tr>
<td>Phase Ia 12 weeks (day 85)</td>
<td>50</td>
<td>62</td>
<td>40</td>
<td>62</td>
<td>30</td>
<td>52</td>
<td>10</td>
<td>55</td>
</tr>
<tr>
<td>Phase Ib 16 weeks</td>
<td>30</td>
<td>78</td>
<td>7</td>
<td>40</td>
<td>29</td>
<td>78</td>
<td>18</td>
<td>40</td>
</tr>
</tbody>
</table>

Proportion of patients achieving the following scores at end point of study, %

<table>
<thead>
<tr>
<th>Study groups</th>
<th>Placebo (N=16)</th>
<th>Dupilumab (N=51)</th>
<th>Placebo (N=54)</th>
<th>Dupilumab (N=55)</th>
<th>Placebo + topical GCS (N=10)</th>
<th>Dupilumab + topical GCS (N=21)</th>
<th>Placebo (N=61)</th>
<th>Dupilumab (N=63)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase Ia 4 weeks (day 29)</td>
<td>19</td>
<td>59</td>
<td>20</td>
<td>69</td>
<td>35</td>
<td>85</td>
<td>50</td>
<td>100</td>
</tr>
<tr>
<td>Phase Ia 12 weeks (day 85)</td>
<td>50</td>
<td>62</td>
<td>40</td>
<td>62</td>
<td>30</td>
<td>52</td>
<td>10</td>
<td>55</td>
</tr>
<tr>
<td>Phase Ib 16 weeks</td>
<td>30</td>
<td>78</td>
<td>7</td>
<td>40</td>
<td>29</td>
<td>78</td>
<td>18</td>
<td>40</td>
</tr>
</tbody>
</table>

Mean % change in the following scores at end point of study

<table>
<thead>
<tr>
<th>Study groups</th>
<th>Placebo (N=16)</th>
<th>Dupilumab (N=51)</th>
<th>Placebo (N=54)</th>
<th>Dupilumab (N=55)</th>
<th>Placebo + topical GCS (N=10)</th>
<th>Dupilumab + topical GCS (N=21)</th>
<th>Placebo (N=61)</th>
<th>Dupilumab (N=63)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase Ia 4 weeks (day 29)</td>
<td>19</td>
<td>59</td>
<td>20</td>
<td>69</td>
<td>35</td>
<td>85</td>
<td>50</td>
<td>100</td>
</tr>
<tr>
<td>Phase Ia 12 weeks (day 85)</td>
<td>50</td>
<td>62</td>
<td>40</td>
<td>62</td>
<td>30</td>
<td>52</td>
<td>10</td>
<td>55</td>
</tr>
<tr>
<td>Phase Ib 16 weeks</td>
<td>30</td>
<td>78</td>
<td>7</td>
<td>40</td>
<td>29</td>
<td>78</td>
<td>18</td>
<td>40</td>
</tr>
</tbody>
</table>

Notes: Subjects were adults older than 18 years with moderate-to-severe AD as defined by an IGA score of ≥3, a baseline EASI score of ≥12, and duration of disease of ≥3 years. Dupilumab refers to subjects receiving all doses. Dupilumab refers to patients receiving the 300 mg dose every other week. All mean percent changes were calculated as percent change in least squares mean.

Abbreviations: AD, atopic dermatitis; EASI, Eczema Area and Severity Index; EASI-50, proportion of patients at 50% reduction in EASI; EASI-75, proportion of patients at 75% reduction in EASI; GCS, glucocorticoids; IGA, Investigator's Global Assessment; N/A, not assessed; SCORAD, Scoring Atopic Dermatitis; SE, standard error.
assigned to receive subcutaneous placebo (n=61) or dupilumab 100 mg (n=65) monthly, 300 mg (n=65) monthly, 200 mg (n=61) every 2 weeks, 300 mg (n=64) biweekly, and 300 mg (n=63) weekly. By week 16, dupilumab showed improved EASI scores and resulted in significant improvement in SCORAD (Scoring Atopic Dermatitis) scores in a dose-dependent manner (Table 1). All of the 300 mg dupilumab dose regimens resulted in more than 3 points decrease in pruritus NRS scores in 37%–54% of subjects versus 8% of subjects in the placebo group. Furthermore, dupilumab resulted in early and sustained improvement in depression, anxiety, and quality-of-life scores. Mean percentage changes in TARC at week 16 correlated with clinical outcomes such as EASI, SCORAD, and IGA scores.29

**Dupilumab: Phase III trials**
In 2016, two identically designed Phase III trials of dupilumab were carried out for subjects with moderate-to-severe AD. Subjects were randomly assigned in a 1:1:1 ratio to receive, subcutaneous 300 mg dupilumab or placebo weekly or the same dose of dupilumab every other week alternating with placebo for 16 weeks. The primary outcome was the proportion of subjects who had both a score of 0 or 1 (clear or almost clear) on IGA and a reduction of 2 points or more in that score from baseline at week 16. Over 600 patients participated in each trial, with 671 subjects for SOLO 1 and 708 subjects for SOLO 2 randomized to receive dupilumab or placebo. In SOLO 1, the primary outcome point was achieved by 38% of patients receiving dupilumab every other week, 37% of those receiving dupilumab weekly, and 10% of subjects who received placebo (Table 2). SOLO 2 demonstrated comparable results, with 36% of patients in both dupilumab groups and 8% of the placebo group reaching the primary outcome point. Additionally, those in the placebo group received more rescue treatment than those in the dupilumab groups.30

In both trials, dupilumab significantly decreased patient-reported symptoms of AD, with improvement in sleep, anxiety, depression, and, therefore, quality of life of subjects. In Dermatology Life Quality Index (DLQI) and Patient-Oriented Eczema Measure (POEM) scores, dupilumab groups demonstrated twice as much improvement compared to placebo groups. At week 16, among the subjects who had Hospital Anxiety and Depression Scale (HADS)-Anxiety or HADS-Depression scores ≥ at baseline, significantly more dupilumab-treated subjects had HADS scores of <8 compared to the placebo group.30

In a 1-year-long randomized, double-blinded, placebo-controlled clinical trial (LIBERTY AD CHRONOS),

---

**Table 2: Clinical efficacy and safety in Phase III trials**

<table>
<thead>
<tr>
<th>Study</th>
<th>Phase and end of study</th>
<th>Placebo</th>
<th>Dupilumab</th>
<th>EOW</th>
<th>Weekly</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase III 16 weeksb</td>
<td>(N=224)</td>
<td>(N=223)</td>
<td>(N=236)</td>
<td>(N=233)</td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>25</td>
<td>25</td>
<td>61</td>
<td>61</td>
<td></td>
</tr>
<tr>
<td>EASI-50</td>
<td>69</td>
<td>69</td>
<td>52</td>
<td>52</td>
<td></td>
</tr>
<tr>
<td>EASI-70</td>
<td>37</td>
<td>37</td>
<td>48</td>
<td>48</td>
<td></td>
</tr>
<tr>
<td>EASI-90</td>
<td>80</td>
<td>80</td>
<td>69</td>
<td>69</td>
<td></td>
</tr>
<tr>
<td>IGA of 0/1 and ≤</td>
<td>45</td>
<td>45</td>
<td>54</td>
<td>54</td>
<td></td>
</tr>
<tr>
<td>SCORAD (SE)</td>
<td>37</td>
<td>37</td>
<td>51</td>
<td>51</td>
<td></td>
</tr>
<tr>
<td>LS mean % change in the following scores at end point of study</td>
<td>−67.1 (2.5)</td>
<td>−69.1 (2.5)</td>
<td>−63.2 (2.2)</td>
<td>−63.2 (2.2)</td>
<td></td>
</tr>
<tr>
<td>EASI-50</td>
<td>−75.7 (2.8)</td>
<td>−75.0 (2.8)</td>
<td>−69.1 (2.5)</td>
<td>−69.1 (2.5)</td>
<td></td>
</tr>
<tr>
<td>EASI-70</td>
<td>−72.0 (2.6)</td>
<td>−72.0 (2.6)</td>
<td>−66.2 (2.3)</td>
<td>−66.2 (2.3)</td>
<td></td>
</tr>
</tbody>
</table>

Notes: Subjects were adults older than 18 years with moderate-to-severe AD as defined by an IGA score of ≥3, a baseline EASI score of ≥16, baseline BSA of ≥10%, and duration of disease of ≥3 years. Dupilumab refers to the 300 mg subcutaneous dose regimen. Placebo: subcutaneous placebo. EOW: every other week. Weekly: subcutaneous dupilumab 300 mg weekly. LS: least squares mean. SCORAD: Scoring Atopic Dermatitis. SE: standard error.
dupilumab was evaluated as concomitant therapy with TCSs in adults with moderate-to-severe AD and inadequate response to TCSs alone. Subjects were randomized in a 3:1:3 ratio to receive subcutaneous 300 mg dupilumab weekly (n=319), 300 mg dupilumab every 2 weeks (n=106), or placebo (n=315), with all three groups receiving concomitant TCSs with or without topical calcineurin inhibitors (TCI) tapered, discontinued, or restarted on the basis of disease activity. By week 16, 39% of patients in each dupilumab group achieved the coprimary endpoint of IGA 0/1 compared to 12% in the placebo group (Table 2). The other coprimary endpoint of 75% reduction in EASI score (EASI-75) was achieved by 64% of the weekly dupilumab group, 69% of the dupilumab every other week group, and 23% of the placebo group. Overall, patients receiving dupilumab had more days free of TCSs/TCI and/or systemic rescue medication use than those in the placebo group at 16 weeks and 52 weeks. Additionally, corresponding SCORAD, POEM, HADS, and DLQI scores were significantly reduced in the dupilumab groups compared to the placebo group. Improvement of NRS and DLQI scores in all three Phase III trials for dupilumab patients is demonstrated in Figures 2 and 3.

### Discussion

Literature concerning the impact of dupilumab in the pathogenesis of AD includes Phase I, II, and III clinical trials. Results from these trials show that dupilumab improves clinical symptoms of moderate-to-severe AD and decreases T-cell markers, markers of epidermal proliferation, and inflammatory mediators and chemokines. In particular, compared to placebo and lower doses, the 300 mg dose of dupilumab demonstrated the greatest improvement in EASI and NRS scores, and transcriptome of lesional skin in Phase I and II studies. Moreover, the 300 mg dose every other week resulted in similar...
efficacy to the 300 mg weekly dose in achieving primary and secondary outcome measures in Phase III trials. Notably, the greatest percentage of patients achieved improvement in EASI or IGA when dupilumab was administered at 300 mg every other week with concomitant TCS use.

Additionally, the frequency of adverse events was demonstrated to be similar between placebo and dupilumab groups, with the most commonly reported adverse events including headaches and nasopharyngitis in Phase I and II trials. In comparison, the most common adverse events reported in Phase III trials were exacerbations of AD (10%–18%), injection-site reactions (15%–19%), and nasopharyngitis (10%–23%), with conjunctivitis also occurring in 14% or more of patients on dupilumab in the 1-year-long Phase III trial. Of note, in Phase I and II trials dupilumab also demonstrated decreased total number of skin infections compared to placebo (4%–5% versus 10%–24%). Moreover, across the four Phase I and II trials, the rate of skin infections in the placebo groups was 0.2 per patient compared to 0.05 infections per patient in the dupilumab groups. This particular finding supports the concept that dupilumab improves epidermal barrier function.

In addition to its clinical efficacy, dupilumab also demonstrated improved quality of life as well, with significant reduction of DLQI and POEM scores. Overall, these results suggest that IL-4 and IL-13 are important mediators in the pathogenesis and morbidity of AD. However, additional trials over an extended period of time are necessary to establish a long-term safety and efficacy profile of dupilumab.

The recent recognition of AD as a predominantly Th2-mediated disease has led the way for the investigation of a variety of therapeutics that target specific inflammatory mediators involved in innate immunity. Multiple biologics are currently being investigated in clinical trials, including antibodies that specifically target IL-13, IL-17, IL-22, IL-31, and IL-12/IL-23p40. Topical and oral phosphodiesterase-4 inhibitors are also being investigated in Phase II and Phase III clinical trials, along with a JAK inhibitor and therapeutics targeting thymic stromal lymphopoietin and che moa attractant receptor-homologous molecule expressed on TH2 cells. These novel therapies have shown promising results. Notably, IL-31 inhibition has shown significant reduction of pruritus in patients with AD. Yet, despite these ongoing investigations into the use of multiple biologics for treatment of AD, dupilumab remains the first and only biologic to be approved for moderate-to-severe AD.

Prior to the development of dupilumab, treatments available for AD included topical and oral glucocorticoids, calcineurin inhibitors, cyclosporine, methotrexate, azathioprine, and mycophenolic acid precursors. Currently, there are no studies comparing dupilumab to other systemic treatments approved for AD. However, prior to the approval of dupilumab, a systematic review of 34 randomized control trials involving 1,653 patients compared the efficacy and safety of 12 systemic treatments using the Grading of Recommendations Assessment, Development, and Evaluation approach. Azathioprine and methotrexate were recommended as second- and third-line treatments, respectively, according to moderate-quality evidence. Cyclosporine A (CsA) received the strongest recommendation as a first-line treatment for short-term use in AD. Additionally, evidence based on four trials demonstrated that long-term treatment with CsA can be recommended for up to 1 year. However, comparison of associated risks of long-term use of CsA, such as nephrotoxicity and hypertension, to that of year-long use of dupilumab, such as nasopharyngitis and conjunctivitis, suggests that dupilumab is likely a safer long-term option. Yet, due to variations in trial designs, it is problematic to compare safety and efficacy data between studies of systemic treatments and dupilumab.

Future evaluations should focus on comparing the efficacy and safety of dupilumab against available systemic treatments in head-to-head trials. In addition, further studies observing the long-term efficacy and safety of dupilumab are also needed. In particular, extended observation to assess immunogenicity is warranted. Specifically, an assessment of the development of neutralizing antibodies over long-term use may provide further insight into how immunogenicity may affect long-term efficacy of dupilumab. Overall, the administration of dupilumab every other week and its relative safety and efficacy offer a convenient and lower-risk alternative to currently available systemic treatments for moderate-to-severe AD.

Disclosure
Dr Alison Ehrlich is an investigator for Sun Pharmaceuticals, Abbvie, Pfizer, UCB Biopharma, Merck, Leo Pharma, Eli Lilly, and is a speaker for Eli Lilly, Celgene, and Abbvie. Dr Alison Ehrlich was also a former principal investigator for the SOLO 2 trial. Dr Olabola Awasika’s fellowship is funded by Janssen Biotech, Inc. The authors report no other conflicts of interest in this work.

References


